Trial
NCT05310071
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Biogen
Collaborators
—
Condition
Alzheimer's Disease
Intervention
Aducanumab
Why stopped
Sponsor's Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-23